Diana Escolar MD FAAN (She/Her)

Neurology•McLean, VA

Neuromuscular Medicine, Neurophysiology

Clinical Drug Development Executive

Join to View Full Profile

A Blue Dot, LLCBuilding 300, Suite201McLean, VA 22101

Education & Training

Childrens HospitalFellowship, Pediatric Neuromuscular/ Electromyography (Lahey Clinic Program), 1992 - 1993
Lahey ClinicFellowship, Neuromuscular Medicine (Neurology), 1992 - 1993
Boston University Medical CenterResidency, Neurology, 1989 - 1992
Waltham Weston Hospital Medical CenterInternship, Transitional Year, 1988 - 1989
University of Buenos AiresClass of 1987

Certifications & Licensure

MD State Medical License 2010 - 2026
VA State Medical License 2023 - 2026
DC State Medical License 1993 - 2013
American Board of Psychiatry and Neurology Neurology

Clinical Trials

Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy Start of enrollment: 2000 Jun 01
Completed
Phase 2, Phase 3
Pentoxifylline in Duchenne Muscular Dystrophy Start of enrollment: 2002 Mar 01
Completed
Phase 1, Phase 2
High-dose Prednisone in Duchenne Muscular Dystrophy Start of enrollment: 2004 Jan 01
Completed
Phase 3
Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy Start of enrollment: 2005 Sep 01
Completed
Phase 1, Phase 2
Open Label Extension Study of HT-100 in Patients With DMD Start of enrollment: 2013 Oct 01
Terminated
Phase 2
HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02 Start of enrollment: 2015 May 01
Terminated
Phase 2
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL Start of enrollment: 2016 Feb 09
Completed
Phase 1
Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids Start of enrollment: 2018 Jun 11
Completed
Phase 2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MRG-110 Following Intradermal Injection in Healthy Volunteers Start of enrollment: 2018 Apr 09
Completed
Phase 1
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides Start of enrollment: 2019 Apr 02
Terminated
Phase 2
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study Start of enrollment: 2019 Oct 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

79 citations
Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo.
Eleni Anastasiadou, Anita G. Seto, Xuan Beatty, Melanie Hermreck, Maud-Emmanuelle Gilles
Clinical Cancer Research. 2021-02-15
33 citations
Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders.
Holly L. Peay, Barbara B. Biesecker, Benjamin S. Wilfond, Jill Jarecki, Kendall L. Umstead
Clinical Trials. 2018-02-23
157 citations
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Craig Campbell, Hugh J. McMillan, Jean K. Mah, Mark A. Tarnopolsky, Kathryn Selby
Muscle & Nerve. 2017-04-01

Press Mentions

Chutes & Ladders—GSK Vaccine Exec Reichman Splits to Take Biotech CEO PostJanuary 22nd, 2021
Diem Nguyen Tapped to Lead 'Point of Inflection' at Xalud Therapeutics; Diana Escolar Dances Her Way to Avrobio CMOJanuary 22nd, 2021
miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, IncOctober 28th, 2020